| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C12H14N2 |
| Molar mass | 186.258 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Altinicline (SIB-1508Y,SIB-1765F) is a drug which acts as anagonist at neuralnicotinic acetylcholine receptors with high selectivity for theα4β2 subtype.[1][2] It stimulates release ofdopamine andacetylcholine in the brain in both rodent and primate models,[3] and progressed as far as Phase IIclinical trials forParkinson's disease,[4] where "no antiparkinsonian or cognitive-enhancing effects were demonstrated", although its current status is unclear.
Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |